Document Detail

Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial).
MedLine Citation:
PMID:  21684068     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Standard treatment for upper urinary tract urothelial carcinoma (UUTUC) is nephroureterectomy. Subsequently, around 40% of patients will develop a bladder tumour potentially because of implantation from the primary tumour.
OBJECTIVE: To prevent bladder tumour after nephroureterectomy with a single postoperative dose of intravesical mitomycin C (MMC).
DESIGN, SETTING, AND PARTICIPANTS: A prospective, randomised, nonblinded trial (ODMIT-C: One Dose Mitomycin C) was undertaken in 46 British centres between July 2000 and December 2006. The study recruited 284 patients with no previous or concurrent history of bladder cancer undergoing nephroureterectomy for suspected UUTUC.
INTERVENTION: A single postoperative intravesical dose of MMC (40 mg in 40 ml saline) or standard management on removal of the urinary catheter.
MEASUREMENTS: Bladder tumour formation was judged by visual appearance at cystoscopy at 3, 6, and 12 mo following nephroureterectomy.
RESULTS AND LIMITATIONS: One hundred forty-four patients were randomised to receive MMC and 140 patients to receive standard care. In the MMC arm, 105 of 144 patients (73%) and 115 of 140 patients (82%) in the standard care arm received their allocated treatment. Thirteen of 105 patients who received MMC and 20 of 115 patients allocated to standard treatment did not complete follow-up. By modified intention-to-treat analysis, 21 of 120 patients (17%) in the MMC arm developed a bladder recurrence in the first year compared to 32 of 119 patients (27%) in the standard treatment arm (p=0.055). By treatment as per protocol analysis, 17 of 105 patients (16%) in the MMC arm and 31 of 115 patients (27%) in the standard treatment arm developed a recurrence (p=0.03). No serious adverse events were reported. A limitation is that histologic proof of recurrence was not required in this trial.
CONCLUSIONS: A single postoperative dose of intravesical MMC appears to reduce the risk of a bladder tumour within the first year following nephroureterectomy for UUTUC. The absolute reduction in risk is 11%, the relative reduction in risk is 40%, and the number needed to treat to prevent one bladder tumour is nine.
Tim O'Brien; Eleanor Ray; Rajinder Singh; Bola Coker; Ralph Beard;
Related Documents :
9267838 - Epilepsy and everyday life risks. a case-referent study: rationale, study design, and p...
1344778 - Absence epilepsy: early prognostic signs.
3279338 - Barbiturate anesthesia in the treatment of status epilepticus: clinical experience with...
17453148 - Discovery of serum biomarkers in astrocytoma by seldi-tof ms and proteinchip technology.
23699538 - A prospective study of the incidence and complications of obstructive sleep apnea (osa)...
22887848 - A vasculitis centre based management strategy leads to improved outcome in eosinophilic...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2011-06-12
Journal Detail:
Title:  European urology     Volume:  60     ISSN:  1873-7560     ISO Abbreviation:  Eur. Urol.     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-08-31     Completed Date:  2012-01-10     Revised Date:  2012-03-06    
Medline Journal Info:
Nlm Unique ID:  7512719     Medline TA:  Eur Urol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  703-10     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Urology Centre, Guys Hospital, Guys and St Thomas' NHS Foundation Trust, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibiotics, Antineoplastic / therapeutic use*
Carcinoma / secondary,  surgery*
Kidney Neoplasms / pathology,  surgery*
Middle Aged
Mitomycin / therapeutic use*
Nephrectomy / methods*
Treatment Outcome
Ureter / surgery
Ureteral Neoplasms / pathology,  surgery*
Urinary Bladder Neoplasms / drug therapy,  prevention & control*,  secondary
Urothelium / pathology
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 50-07-7/Mitomycin
Comment In:
Eur Urol. 2012 Feb;61(2):426-7   [PMID:  22186348 ]
Eur Urol. 2012 Mar;61(3):e14; author reply e15   [PMID:  22189381 ]
Eur Urol. 2011 Oct;60(4):711-2   [PMID:  21715085 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mechanical Stimuli-induced Urothelial Differentiation in a Human Tissue-engineered Tubular Genitouri...
Next Document:  Laparoendoscopic Single-site Surgery in Urology: Worldwide Multi-institutional Analysis of 1076 Case...